StonvexLoading…
StonvexStonvexStonvexLive corporate press releases for NYSE & NASDAQ stocks. OTC excluded. Impact and sentiment are observational classifications, not a recommendation to act.
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
WTW Investors Have Opportunity to Join Willis Towers Watson Public Limited Company Fraud Investigation with the Schall Law Firm
Eight Directions Technology Limited Announces Entering into an Agreement and Plan of Merger with Quartzsea Acquisition Corporation
Nvidia Reports Earnings This Month, and I'm Not Buying Shares. 1 AI Stock to Buy Now Instead.
Wrap Technologies (WRAP) Q1 2026 Earnings Call Transcript
NCLH Investors Have Opportunity to Join Norwegian Cruise Line Holdings Ltd. Fraud Investigation with the Schall Law Firm
60 releases in the last 48h
The Schall Law Firm is seeking investors to join a class action lawsuit against Atara Biotherapeutics for alleged securities fraud. The company allegedly made false and misleading statements regarding manufacturing problems and deficiencies in its ALLELE study for tabelecleucel, overstating the drug's prospects and concealing regulatory risks. Investors who purchased securities between May 20, 2024 and January 9, 2026 are encouraged to participate.
The Schall Law Firm is investigating Willis Towers Watson (WTW) for potential securities law violations related to false or misleading statements. The investigation was triggered after the company reported Q1 2026 results showing declining operating margins and weak organic revenue growth, causing shares to fall 11.7% on April 30, 2026. Investors who suffered losses are encouraged to participate in the class action lawsuit.
Press releases sourced from Polygon.io news feed. OTC tickers are automatically filtered out. Impact and sentiment are classified by AI.
Risk warning
Investing in equities carries significant risk, including the potential loss of your entire investment. Volatility, liquidity, geopolitical, and currency risks can all materially affect outcomes. Past performance does not guarantee future results. Nothing on Stonvex is investment advice, a recommendation, or a solicitation to buy or sell any security. Stonvex is not a registered investment advisor (RIA), broker-dealer, or financial planner. You should consult a licensed advisor before making investment decisions and only invest capital you can afford to lose.
© 2026 Stonvex. All rights reserved.
Service not available to residents of: Belarus, China, Cuba, France, Germany, India, Iran, Japan, North Korea, Russia, Sudan, Syria. See Terms. You must be 18 years or older to use this service.